Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Liabilities (2022 - 2025)

Corvus Pharmaceuticals has reported Total Liabilities over the past 4 years, most recently at $8.7 million for Q3 2025.

  • Quarterly results put Total Liabilities at $8.7 million for Q3 2025, down 81.24% from a year ago — trailing twelve months through Sep 2025 was $8.7 million (down 81.24% YoY), and the annual figure for FY2024 was $36.3 million, up 429.03%.
  • Total Liabilities for Q3 2025 was $8.7 million at Corvus Pharmaceuticals, down from $9.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for CRVS hit a ceiling of $46.4 million in Q3 2024 and a floor of $6.7 million in Q1 2024.
  • Median Total Liabilities over the past 4 years was $10.1 million (2025), compared with a mean of $14.3 million.
  • Biggest five-year swings in Total Liabilities: surged 506.38% in 2024 and later tumbled 81.24% in 2025.
  • Corvus Pharmaceuticals' Total Liabilities stood at $12.1 million in 2022, then crashed by 43.35% to $6.9 million in 2023, then skyrocketed by 429.03% to $36.3 million in 2024, then plummeted by 76.04% to $8.7 million in 2025.
  • The last three reported values for Total Liabilities were $8.7 million (Q3 2025), $9.2 million (Q2 2025), and $10.1 million (Q1 2025) per Business Quant data.